Observational studyActa diabetologica2026
A perspective on clinical profile and quality of care of "Octogenarians" living with type 1 diabetes in Italy, AMD Annals Initiative.
Observational study in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThanks to the efforts made in the last century many patients with Type 1 Diabetes (T1D) are reaching and surpassing the age of 75, however, data on their clinical characteristics, prevalence of diabetes complications and quality of care are lacking.
methodsThis multicenter, observational, retrospective study includes data from participants with T1D aged over 75 years, regularly evaluated in the year 2023 in 296 Diabetes Clinics in Italy included in the Associazione Medici Diabetologi (AMD) Annals Initiative. Socio-demographic characteristics, data on glycemic, lipid, and blood pressure control, data on the current insulin therapy regimen, the use of insulin pumps, as well as data on the prevalence of microvascular and macrovascular complications of diabetes was evaluated. Additionally, we evaluated some indicators of quality of care.
resultsWe included 2443 participants with mean age of 79.9 ± 3.9 years, in prevalence (54.9%) female. The mean duration of diabetes was 34.1 ± 17.5 years. Participants were evaluated regularly in person at the diabetes clinic on average 2.7 ± 2.1 times per year. 5% of participants were treated with insulin pumps. Mean glycated hemoglobin (HbA1c) was 7.8 ± 1.1. In comparison to standard therapy, better glycemic control was seen in participants on insulin pumps. Despite the high prevalence of diabetic retinopathy (33.3%) and chronic kidney disease (CKD) (39%) only a small portion of participants presented with end-stage complication, with 2.3% of participants having Proliferative Retinopathy (0.4% vision loss), 0.3% being on dialysis, and 2.5% having a history of amputation or foot ulcer. Cardiovascular disease was detected in 17.8% of participants. 77% of participants with previous CV event were treated with anti-platelet therapy. 68% of participants with proteinuria were treated with renin-angiotensin-aldosterone system (RAAS) inhibitors. LDL target of < 100 mg/dl was achieved in almost 2/3 of participants. Overall quality of care, expressed as Q-Score, was 27.4 ± 8.2.
conclusionOur data show that a consistent number of T1D participants regularly followed up by Italian diabetes centers reached an advanced age. The overall quality of care for participants regularly followed was good, within a lower-than-expected burden of end-stage renal disease, visual loss, and diabetic foot. Management of CV risk factors could be improved, as well as the use of technology in this setting.
Indexed as
Identifiers
41307692What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.